[[Reactive arthritis].
Klinik und Poliklinik für Innere Medizin, Universitätsspital Zürich. christina.ryser@triemli.stzh.ch
Christina
C
Ryser
Paul
P
Hasler
D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use; D016918:Arthritis, Reactive / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000235:genetics / Q000628:therapy; D017963:Azithromycin / Q000008:administration & dosage / Q000627:therapeutic use; D002690:Chlamydia Infections / Q000175:diagnosis / Q000188:drug therapy; D002692:Chlamydia trachomatis / Q000302:isolation & purification; D003937:Diagnosis, Differential; D005260:Female; D015796:HLA-B27 Antigen; D006239:Haplotypes; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D016133:Polymerase Chain Reaction; D011379:Prognosis; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D012460:Sulfasalazine / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D014556:Urine / Q000382:microbiology
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D015796:HLA-B27 Antigen; D012460:Sulfasalazine; D017963:Azithromycin; D012293:Rifampin